Beyond the 20: Noncanonical Amino Acids Are Reshaping Peptide Drug Discovery

For decades, peptide chemistry was organized around the twenty proteinogenic amino acids. That framework remains essential, but it no longer defines the chemical space of modern peptide drug discovery.

D-amino acids, N-methyl amino acids, α-methyl residues, β- and γ-amino acids, fluorinated residues and other noncanonical amino acids are increasingly being introduced deliberately to solve specific medicinal-chemistry problems: proteolytic instability, poor membrane permeability, weak target affinity, excessive conformational flexibility or inadequate pharmacokinetics.

This shift is important for researchers working with amino acids and peptide building blocks, because the building block is no longer simply a reagent used to reproduce a biological sequence. It is becoming part of the drug-design strategy.

The Data Show That Noncanonical Chemistry Is Moving Into the Mainstream

Several recent observations illustrate how quickly this field is changing.

A 2025 review estimated that peptides represented approximately 8% of FDA drug approvals over the previous decade, while a 2026 review identified more than 20 FDA-approved drugs containing at least one D-amino acid.

At the discovery level, the expansion is even more dramatic. Conventional one-bead-one-compound libraries typically reach approximately 10⁵ to 10⁷ compounds, whereas modern mRNA display can access libraries on the order of 10¹² to 10¹⁴ sequences. Genetic-code reprogramming allows these libraries to include N-methyl, D-, β- and γ-amino acids rather than being limited to the standard twenty residues.

Figure 1. Expansion of peptide chemical space beyond the canonical twenty amino acids.
The figure should contrast conventional peptide libraries based mainly on proteinogenic residues with modern discovery libraries incorporating D-amino acids, N-methyl residues, α-methyl amino acids and other noncanonical building blocks. Library-scale values should be identified as published display-platform data.

Enlicitide Is an Important 2026 Proof Point

Perhaps the strongest recent evidence came in July 2026, when the FDA approved Lipfendra (enlicitide) as the first oral PCSK9 inhibitor. Enlicitide was originally developed as MK-0616 and is a highly engineered macrocyclic peptide discovered through mRNA-display-driven peptide discovery.

Its structure is particularly relevant to building-block chemistry.

Published synthetic analysis describes the largest macrocycle as containing only two conventional amino acids and six nonproteinogenic amino acids, together with additional nonpeptidic structural elements.

Among the medicinal-chemistry strategies used during development were D-Ala, α-methylated residues, fluorinated tryptophan, cross-links and other structural modifications designed to improve potency, stability, solubility and pharmacokinetics.

The clinical outcome demonstrates why this chemistry matters. In a 2026 Phase 3 comparison, enlicitide produced a 64.6% mean reduction in LDL-C at day 56, compared with 27.8% for ezetimibe and 36.5% for the combination of bempedoic acid and ezetimibe.

The important lesson is not that every peptide should contain six unusual residues. It is that noncanonical amino acids have moved beyond being experimental curiosities. They can now be components of clinically and commercially viable peptide architectures.

Figure 2. From noncanonical building blocks to an approved oral macrocyclic peptide.
Recommended data graphic: six nonproteinogenic residues versus two natural residues in the principal enlicitide macrocycle, together with the 2026 FDA approval milestone and the reported 64.6% LDL-C reduction from the Phase 3 AddOn trial. The figure should be clearly labeled as literature-derived data.

Why Noncanonical Amino Acids Can Change Peptide Behavior

A single residue substitution can influence several properties at the same time.

D-amino acids can reduce recognition by proteases because many biological enzymes evolved to recognize L-amino-acid stereochemistry. Alan Scientific's D-form amino acids therefore provide more than a mirror-image version of a conventional residue; they can serve as a practical tool for exploring metabolic stability and conformational effects.

α-Methylated and N-methylated residues can reduce backbone flexibility and alter hydrogen-bonding patterns. These changes may stabilize bioactive conformations or improve membrane permeability, but they can also make coupling more difficult.

Fluorinated and hydrophobic analogs can change binding interactions and metabolic behavior. β- and γ-amino acids alter backbone geometry more fundamentally and can produce structures unavailable to conventional α-amino-acid peptides.

This creates a useful design principle: a noncanonical amino acid should be selected to solve a defined molecular problem, not simply to increase chemical novelty.

More Chemical Space Also Creates a Synthesis Problem

Modern display and computational systems can propose enormous numbers of peptide candidates, but every proposed residue eventually creates a practical synthetic question.

Can the building block be obtained reproducibly? Is the required stereoisomer available? Can it tolerate repeated Fmoc deprotection? Does the side chain require orthogonal protection? Is coupling sufficiently efficient? Will the residue create a new purification problem?

This is where the expansion of computational peptide design is beginning to encounter a physical constraint.

Software can generate candidate sequences faster than specialized chemistry can always be manufactured.

Alan Scientific View: the next bottleneck in AI- and display-driven peptide discovery may not be sequence generation. It may increasingly become building-block accessibility, synthetic feasibility and analytical quality.

This is particularly relevant when AI-guided peptide optimization begins exploring sequence space beyond conventional substitutions. An AI model can rank an exotic residue highly, but a useful design still has to survive synthesis, purification and experimental validation.

The best future peptide-design systems should therefore treat synthetic accessibility as part of candidate ranking rather than as a problem to be solved after design.

D-Amino Acids Are Likely to Become More Routine

Among noncanonical building blocks, D-amino acids are especially interesting because the chemistry is already mature and their biological role is increasingly well established.

The 2026 review of FDA-approved D-amino-acid-containing drugs identified more than twenty approved examples and highlighted etelcalcetide as the first fully D-amino-acid peptide approved by the FDA.

For research peptide programs, this suggests a relatively low-risk strategy for expanding chemical space. Researchers do not always need exotic new chemistry as the first optimization step. Strategic L-to-D substitution at known proteolytic hotspots can sometimes provide a more straightforward experiment.

The same principle applies to standard Fmoc amino acids. Conventional building blocks remain the foundation of peptide synthesis. Noncanonical residues are most powerful when used selectively to alter a property that standard residues cannot adequately control.

The Emerging Trend: Building Blocks and Computational Design Are Converging

The 2025 literature increasingly describes noncanonical amino acids not as optional additions but as important tools in modern peptide discovery. A dedicated Chemical Reviews special issue focused on ncAAs, while a 2025 review argued that incorporation of noncanonical residues early in discovery can accelerate lead optimization and translation.

At the same time, macrocyclic-peptide discovery is becoming increasingly computational. Deep-learning approaches for de novo protein-binding macrocycles emerged prominently in 2025, while display technologies continue to generate extraordinarily large libraries.

These trends are likely to converge.

Future peptide-design platforms will increasingly have to optimize three things simultaneously:

biological performance, molecular properties and synthetic feasibility.

For suppliers and peptide synthesis laboratories, this changes the meaning of a building-block portfolio. The strategic value will no longer come only from stocking the twenty standard Fmoc amino acids. It will come from supporting the increasingly diverse chemistry required to convert computational and display-derived sequences into real molecules.

Conclusion

Noncanonical amino acids are moving from specialty chemistry into the core architecture of peptide drug discovery.

The growth of mRNA display, macrocyclic peptides and computational design is opening chemical spaces that cannot be explored using only the canonical twenty residues. At the same time, recent clinical and regulatory success demonstrates that highly engineered peptide chemistry can translate into real medicines.

The 2026 approval of enlicitide provides a particularly important signal. A macrocyclic peptide containing extensive nonproteinogenic chemistry is no longer simply an interesting discovery program; it has become an approved oral therapeutic.

Alan Scientific View: the next generation of peptide discovery will not be defined by choosing between natural and non-natural amino acids. It will be defined by how intelligently individual building blocks are selected to solve stability, permeability, potency and manufacturability problems.

Researchers developing peptides containing specialized residues can explore Alan Scientific's custom peptide synthesis, D-form amino acids and broader peptide-building-block portfolio.

References

1. Grob NM. Beyond the Canonical 20: Peptide Discovery with Non-Canonical Amino Acids. Chimia. 2025.

2. Schultz DM. Beyond 20 in the 21st Century: Prospects and Challenges of Non-canonical Amino Acids in Peptide Drug Discovery. ACS Medicinal Chemistry Letters. 2023.

3. Obexer R, et al. Diversity Scale of Library Matters. ACS Central Science. 2024.

4. Josien H, et al. Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic. Journal of Medicinal Chemistry. 2026.

5. Catapano AL, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies. JACC. 2026.

6. U.S. Food and Drug Administration. FDA Approves First Oral PCSK9 Inhibitor. July 2026.